Health Catalyst’s (HCAT) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Health Catalyst (NASDAQ:HCAT) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $4.00 price target on the stock.

Several other research firms also recently weighed in on HCAT. Summit Redstone set a $5.00 target price on Health Catalyst in a research report on Friday, August 29th. Piper Sandler cut Health Catalyst from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $4.00 in a report on Wednesday, August 27th. Citigroup cut Health Catalyst from a “buy” rating to a “neutral” rating and decreased their price target for the company from $6.50 to $3.50 in a report on Friday, August 8th. Stifel Nicolaus decreased their price target on Health Catalyst from $5.50 to $4.50 and set a “hold” rating on the stock in a report on Friday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Health Catalyst in a report on Saturday, September 27th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Hold” and a consensus target price of $4.73.

Health Catalyst Price Performance

NASDAQ HCAT opened at $2.85 on Tuesday. The company has a market capitalization of $200.55 million, a PE ratio of -1.89 and a beta of 1.62. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The business’s fifty day moving average is $3.17 and its 200 day moving average is $3.69. Health Catalyst has a fifty-two week low of $2.52 and a fifty-two week high of $9.24.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HCAT. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 99.1% during the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock valued at $47,279,000 after buying an additional 5,195,686 shares during the period. Nepsis Inc. boosted its position in shares of Health Catalyst by 2,072.1% during the first quarter. Nepsis Inc. now owns 2,090,812 shares of the company’s stock valued at $9,471,000 after buying an additional 1,994,555 shares during the period. Whetstone Capital Advisors LLC purchased a new position in shares of Health Catalyst during the first quarter valued at approximately $7,724,000. Nuveen LLC purchased a new stake in shares of Health Catalyst in the first quarter valued at approximately $2,674,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Health Catalyst by 172.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,361 shares of the company’s stock valued at $3,145,000 after purchasing an additional 439,599 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.